Drug Trial Radar · NCT02667938
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules
Last checked: Nov 19, 2026Latest source record: Oct 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
510
Actual
Start
Mar 2015
Primary completion
Jan 2016
Study completion May 2016
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jan 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to evaluate efficacy and safety of HCP1301 capsule in patients with Benign Prostatic Hyperplasia and Erectile Dysfunction
Conditions
- Benign Prostatic Hyperplasia
Interventions
HCP1303 capsule 5/0.2mgDrug
HCP1303 capsule 5/0.4mgDrug
HGP1201Drug
HCP1303 capsule 5/0.2mg placeboDrug
HCP1303 capsule 5/0.4mg placeboDrug
HGP1201 placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of Total IPSS (International Prostate Symptom Score)Time frame: baseline and 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.